6 recruiting, 4 completed, 1 active not recruiting, 1 not yet recruiting. 6 Phase 3, 3 Phase 4, 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 4 | 3 | Recruiting 3 |
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Terminated 1 |
Follow attruby: new trials by email Literature Review of attruby trials Research Report on attruby
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE) Acoramidis (AG10) - Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial | Phase 3 | Not yet recruiting | Eidos Therapeutics, a BridgeBio company | 250 | 2026-11-01 | 2026-08-11 |
| Study of Acoramidis in Patients With Transthyretin Amyloid Cardiomyopathy Acoramidis - Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | Recruiting | Bayer | 500 | 2026-09-07 | 2026-09-15 | |
| Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis Acoramidis (AG10) oral tablet - Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis | Phase 4 | Recruiting | Eidos Therapeutics, a BridgeBio company | 150 | 2026-07-01 | 2026-07-29 |
| A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis Acoramidis - Transthyretin Amyloid Cardiomyopathy | Phase 4 | Recruiting | Bayer | 50 | 2026-02-13 | 2026-10-15 |
| A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting Acoramidis (356 mg film-coated tablets) - Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | Recruiting | Bayer | 2000 | 2025-10-29 | 2026-10-08 | |
| Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers Acoramidis - Transthyretin-type Cardiac Amyloidosis | Phase 4 | Recruiting | Alexion Pharmaceuticals, Inc. | 200 | 2025-10-01 | 2026-01-07 |
| Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant Acoramidis, Placebo oral tablet - Amyloidosis, Amyloid Cardiomyopathy | Phase 3 | Recruiting | Eidos Therapeutics, a BridgeBio company | 587 | 2025-05-12 | 2026-08-04 |
| Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants Acoramidis (AG10) - Amyloid Cardiomyopathy, Transthyretin-Related | Phase 3 | Active not recruiting | Eidos Therapeutics, a BridgeBio company | 389 | 2021-10-27 | 2025-10-14 |
| Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN) Acoramidis - Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | Phase 3 | Withdrawn | Eidos Therapeutics, a BridgeBio company | 2021-09-08 | 2024-09-19 | |
| Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants Acoramidis - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 18 | 2021-05-30 | 2026-03-06 |
| A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects acoramidis - Amyloidosis | Phase 1 | Completed | Eidos Therapeutics, a BridgeBio company | 14 | 2021-03-28 | 2024-09-19 |
| A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM ALXN2060 - Symptomatic Transthyretin Amyloid Cardiomyopathy | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 25 | 2020-11-13 | 2026-06-10 |
| Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy acoramidis, Placebo Oral Tablet - Amyloidosis, Amyloid Cardiomyopathy | Phase 3 | Completed | Eidos Therapeutics, a BridgeBio company | 632 | 2019-03-19 | 2024-06-27 |
| Open-Label Study of AG10 in Patients With Cardiomyopathy Acoramidis - Amyloid Cardiomyopathy | Phase 2 | Terminated | Eidos Therapeutics, a BridgeBio company | 47 | 2018-08-08 | 2026-10-14 |
Amyloid Neuropathies, Familial (7) · Amyloidosis (7) · Alzheimer Disease (6) · Amyloidosis, Hereditary, Transthyretin-Related (6) · Cardiomyopathies (6) · Heart Diseases (3) · Polyneuropathies (3) · Amyloidosis, Familial (2) · Heart Failure (1)
Eidos Therapeutics, a BridgeBio company (8) · Alexion Pharmaceuticals, Inc. (3) · Bayer (3)
United States (6) · Belgium (5) · Italy (5) · United Kingdom (5) · Denmark (4) · Portugal (4) · Spain (4) · Australia (3) · Brazil (3) · Canada (3) · Germany (3) · Greece (3) · Ireland (3) · Japan (3) · Netherlands (3)
Mark McGovern, RN, CCRN (1) · Philip Evans, MBChB, MRCS (1)
PMID 42389794, PMID 41205147, PMID 42622768, PMID 33725199, PMID 38197816, PMID 39556242, PMID 39878480, PMID 40074465, PMID 40216220, PMID 40398971, PMID 40750720, PMID 41384357, PMID 41911489, PMID 42110872, PMID 42216490, PMID 42307157, PMID 42525404, PMID 42533192, PMID 42554365, PMID 42669902
2018 (1), 2025 (1)